To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 690
- Registration Number
- NCT04709328
The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT04683328
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 795
- Registration Number
- NCT04644185
- Locations
- 🇵🇪
SCT study site, Lima, Peru
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04564937
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 405
- Registration Number
- NCT04560894
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT04483375
- Locations
- 🇨🇳
Beijing SHIJITAN Hospital, Beijing, Beijing, China
Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04229537
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT04171284
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT04146181
- Locations
- 🇨🇳
Guangxi Medical University Affiliated Tumour Hospital, Nanning, Guangxi, China
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT04146402
- Locations
- 🇨🇳
The Third Affiliated Hospital Of Qiqihar Medical University, Qiqihar, China
© Copyright 2024. All Rights Reserved by MedPath